论文部分内容阅读
目的观察支肺合剂Ⅰ号、Ⅱ号、Ⅲ号治疗三种证型支原体肺炎患儿主要、次要症状及体征的影响。方法将70例肺炎支原体肺炎患儿随机分为对照组(38例)和治疗组(32例)。两组均静脉滴注阿奇霉素,口服氨溴特罗口服溶液,治疗组根据辨证分型分别加服支肺合剂Ⅰ号、Ⅱ号、Ⅲ号。观察两组治疗前后主要、次要症状及体征(主要:发热、咳嗽、痰壅、气促、乏氧;次要:恶寒、心率、面色、精神、食欲、出汗)改善情况。结果病例脱落7例。与本组治疗前比较,两组治疗后主要、次要症状及体征评分均降低(P<0.01);对照组治疗后发热及咳嗽均明显改善(P<0.01),治疗组治疗后症状、体征均明显改善(P<0.01)。与对照组比较,治疗组治疗后主要症状及体征评分下降程度更大(P<0.01),患儿主要症状、体征改善更明显(P<0.05)。结论支肺合剂联合西药能显著改善支原体肺炎患儿主要及次要症状、体征,效果优于单用西药。
Objective To observe the main, minor symptoms and signs of Zhu Fei Mixture Ⅰ, Ⅱ and Ⅲ in treating children with three syndromes of mycoplasma pneumonia. Methods Seventy patients with Mycoplasma pneumoniae pneumonia were randomly divided into control group (38 cases) and treatment group (32 cases). Azithromycin was intravenously administered to both groups and oral ambroxol solution was given to the patients in the treatment group. The patients in the treatment group were given bronchodilators Ⅰ, Ⅱ and Ⅲ respectively according to syndrome differentiation. The main and minor symptoms and signs (mainly: fever, cough, phlegm, shortness of breath, hypoxia; minor: aversion to cold, heart rate, looking, spirit, appetite, sweating) of the two groups were observed before and after treatment. Results 7 cases of cases off. Compared with the group before treatment, the main symptoms and signs of the two groups were decreased after treatment (P <0.01). The fever and cough of the control group were significantly improved after treatment (P <0.01). The symptoms and signs Were significantly improved (P <0.01). Compared with the control group, the main symptoms and signs of the treatment group decreased significantly (P <0.01), and the improvement of the main symptoms and signs in the treatment group was more obvious (P <0.05). Conclusions: The combination of Zhu Fei Hei and western medicine can significantly improve the primary and secondary symptoms and signs in children with mycoplasmal pneumonia, and the effect is better than that of western medicine alone.